Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma
Y Ito, T Takeda, M Sakon, M Tsujimoto, S Higashiyama, K Noda, E Miyoshi, M Monden, N Matsuura, Y Ito, T Takeda, M Sakon, M Tsujimoto, S Higashiyama, K Noda, E Miyoshi, M Monden, N Matsuura
Abstract
In order to elucidate the clinical significance of the erbB family, epidermal growth factor receptor (EGF-R), c-erbB-2, c-erbB-3 and c-erbB-4 in hepatocellular carcinoma (HCC), we investigated the expression of these proteins by means of immunohistochemistry for HCC as well as adjacent noncancerous lesions. EGF-R was expressed in 68% of the HCC examined and showed correlation with the proliferating activity, stage, intrahepatic metastasis and carcinoma differentiation. c-erbB-2 was expressed in only 21% of the cases and showed no relationships with the clinicopathological parameters. c-erbB-3 protein was observed in 84% of the HCC and 38.1% of the noncancerous lesions. Its expression in HCC was equal to or greater than noncancerous lesions in 90.5% of the cases, and was related to the stage, portal invasion, cell proliferating activity, tumour size, intrahepatic metastasis and carcinoma differentiation. c-erbB-4 protein was expressed in 61.0% of HCC and in as much as 86.1% of the noncancerous lesions. Unlike the expression of c-erbB-3, that of c-erbB-4 in HCC was less than that of the adjacent noncancerous lesions in 51.2% of the cases. No statistical significance could be established between this protein expression in HCC and clinicopathological features. EGF-R and c-erbB-3 affected disease-free survival, but were not recognized as independent prognostic factors by multivariate analysis. The present study suggests that, of the four receptors, EGF-R and c-erbB-3 play important roles in the progression of HCC.
Copyright 2001 Cancer Research Campaign.
References
- Int J Cancer. 1995 Jun 22;64(3):202-6
- World J Surg. 1999 Oct;23(10):1010-8
- Am J Pathol. 1996 Feb;148(2):549-58
- Cancer Res. 1996 Mar 15;56(6):1184-8
- J Biol Chem. 1996 Mar 1;271(9):5251-7
- EMBO J. 1996 May 15;15(10):2452-67
- Anticancer Res. 1995 Nov-Dec;15(6B):2623-6
- Br J Cancer. 1996 Jul;74(2):229-33
- Pathol Res Pract. 1995 Nov;191(11):1087-91
- Pancreas. 1997 Apr;14(3):229-36
- EMBO J. 1997 Mar 17;16(6):1268-78
- Anticancer Res. 1997 Mar-Apr;17(2A):1023-6
- Anticancer Res. 1997 Mar-Apr;17(2B):1319-30
- Virchows Arch. 1997 Jun;430(6):461-6
- Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9562-7
- Liver. 1997 Aug;17(4):177-82
- Oncogene. 1997 Dec 4;15(23):2841-8
- Eur J Cancer. 1997 Oct;33(11):1846-50
- Anticancer Res. 1997 Nov-Dec;17(6D):4539-46
- J Pathol. 1998 Jul;185(3):236-45
- Histopathology. 1998 Oct;33(4):325-31
- Histopathology. 1998 Dec;33(6):514-21
- Hum Pathol. 1999 Sep;30(9):1077-86
- Clin Cancer Res. 1999 Oct;5(10):2877-83
- Br J Cancer. 1999 Oct;81(4):747-51
- Br J Cancer. 2000 Mar;82(6):1163-70
- Cancer Res. 2000 Mar 15;60(6):1483-7
- J Cancer Res Clin Oncol. 2000 Apr;126(4):205-11
- Lancet. 1981 Nov 21;2(8256):1129-33
- IARC Sci Publ. 1984;(63):59-88
- Anal Biochem. 1987 Apr;162(1):156-9
- J Cell Physiol. 1987 Dec;133(3):579-84
- Proc Natl Acad Sci U S A. 1989 Dec;86(23):9193-7
- Cell. 1990 Apr 20;61(2):203-12
- Cancer Res. 1990 Jul 1;50(13):4087-91
- Cancer Res. 1990 Jul 15;50(14):4332-7
- Cancer Res. 1990 Aug 15;50(16):5184-7
- Proc Natl Acad Sci U S A. 1990 Sep;87(17):6547-9
- Cancer Res. 1990 Dec 15;50(24):8002-9
- Cell. 1991 Jan 25;64(2):281-302
- Am J Clin Pathol. 1992 May;97(5 Suppl 1):S53-61
- J Hepatol. 1992 Mar;14(2-3):377-80
- Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1746-50
- Int J Cancer. 1993 Jul 30;54(6):935-40
- J Biol Chem. 1993 Sep 15;268(26):19312-20
- Mol Cell Biol. 1994 Jun;14(6):3550-8
- J Biol Chem. 1994 Oct 7;269(40):24747-55
- Histol Histopathol. 1994 Oct;9(4):677-82
- Oncogene. 1996 Jan 18;12(2):345-53
Source: PubMed